my account
Login
  Loading... Please wait...

New Products

We will continue to add new products to our already extensive portfolio - check back often for the latest breakthroughs. If you can't find what you need, contact us for information on custom synthesis.

 

10-1543

08/20

BTB-1 | Mitotic kinesin Kif18A inhibitor

Selective, ATP-competitive and reversible inhibitor of mitotic kinesin Kif18A. Suppresses the replication of influenza A virus,

 

10-2064

08/20

Chromomycin A3 | DNA Stain

DNA-binding agent specific for GC-rich sequences which may be used as a DNA stain. Inhibits neuronal apoptosis induced by oxidative stress and DNA damage.

 

 

10-2069

08/20

Cytochalasin B | Actin filament disrupting agent

Cell permeable fungal toxin which binds to the barbed end of actin, inhibiting its polymerization. Inhibits cell division, migration and glucose transport.

 

10-2923

08/20

Oleamide | Endogenous sleep inducing ligand

Displays agonist activity at cannabinoid CB1 receptors. Activates PPARγ. Displays neuroprotective effects and attenuates sepsis-induced intestinal injury.

 

10-3497

08/20

WP631 | Inhibits SP-1 activated transcription

Potent inhibitor of Sp1-activated transcription. Induces caspase-dependent apoptosis in human ovarian cancer cells.

 

 

10-3538

08/20

Tomentosin | Inhibitor of NFkB activation

It suppresses the production of inflammatory mediators by inhibiting NFκB activation. Induces Apoptosis in some cancer cell lines.

 

10-3781

08/20

Dodecyl-TPP | Mitochondrial-targeted cancer stem cell inhibitor

Inhibits mitochondrial function inhibiting oxidative phosphorylation and shifting cell metabolism to glycolysis. Potently eradicates cancer stem cells selectively over normal cells.

 

10-3879

08/20

4-MUG | beta-Glactosidase fluorogenic substrate

Versatile fluorogenic substrate for β-galactosidase1 for use in cell extracts or purified enzyme preparations.

 

10-4655

08/20

AE 51310 | OPN4/Melanopsin antagonist

Potent antagonist of the GPCR OPN4/melanopsin. OPN4 regulates circadian rhythms, pupil functions, melatonin expression, cognition, and sleep.

 

10-4685

08/20

BO-264 | TACC3 inhibitor

Potent inhibitor of transforming acidic coiled-coil 3 (TACC3), an important protein involved in microtubule stability and centrosome integrity.

 

 

10-4751

08/20

Ipatasertib | Pan-AKT inhibitor

Selective and potent pan-Akt inhibitor. It displayed efficacy in xenograft models of prostate, breast, ovarian, colorectal, non-small cell lung, glioblastoma, and melanoma cancers.

 

10-4925

08/20

SX-682 | CXCR1/2 inhibitor

Novel CXCR1/2 inhibitor. It displayed robust synergistic activity with immune checkpoint blockade against castration resistant prostate cancer.

 

10-5034

08/20

Brigatinib | pan-ALK inhibitor

Potent and selective pan-ALK inhibitor. Cells with ALK mutation L1196Q2 and the double mutation I1171S + G12693 remain sensitive to brigatinib.

 

10-5103

08/20

AS-1949490 | SHIP2 inhibitor

Potent and selective inhibitor of the intracellular phosphatase SHIP2. Displays ca. 30-fold selectivity for SHIP2 over SHIP1.

 

10-5124

08/20

WH-4-023 | Src family inhibitor

Potent and selective Src family kinase inhibitor known to inhibit Lck, Src, SIK1, SIK2 and SIK3.

 

10-5144

08/20

NQDI-1 | ASK1 inhibitor

Selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1). Promotes survival of induced pluripotent stem cells.

 

10-5145

08/20

Filgotinib | JAK1 inhibitor

Potent and selective JAK1 inhibitor. Displays potent anti-inflammatory activity in various models.

 

10-3519

07/20

CPI-613 | KGDH and PDH inhibitor

Lipoic acid analog which potently disrupts mitochondrial metabolism with selectivity for tumor cells in vitro and shows strong antitumor activity in vivo.

 

10-3895

07/20

Dyclonine HCl | Mitochondrial function enhancer

Topical anesthetic which has been used for oral and throat analgesia. Enhances neuronal mitochondrial function, potentiating respiration and providing protection against insults associated with neurodegenerative disorders.

 

10-4012

07/20

URMC-099 | Mixed-lineage kinase inhibitor

Potent, brain penetrant mixed-lineage kinase 3 inhibitor (MLK3). It also potently inhibits FLT3, LRRK2, and ABL1.

 

10-4034

07/20

PFI-3 | Family VIII bromodomain inhibitor

Selective inhibitor of family VIII bromodomains PB1(5), SMARCA2, and SMARCA4. Shows complete selectivity over all non-family VIII bromodomains.

 

 

10-4665

07/20

PB28 dihydrochloride | High affinity sigma 2 ligand / Anti-SARS-CoV2

Very potent high affinity (Ki = 5.3 nM1, 0.34 nM2) σ2 agonist. Selective for σ2 over σ1. PB28 inhibited cell growth in MCF7 and MCF7 ADR breast cancer cells and displayed strong synergism with doxorubicin

 

10-4675

07/20

Liproxstatin-1 | Ferroptosis inhibitor

Inhibitor of ferroptosis. Liproxstatin-1’s mechanism of activity has been attributed to its activity as a radical-trapping antioxidant.

 

10-4792

07/20

GSK2982772 | RIPK1 inhibitor

Highly selective inhibitor of Receptor-interacting Protein 1 kinase.

 

10-5047

07/20

Fludarabine | DNA synthesis inhibitor

Synthetic adenosine analog that inhibits DNA biosynthesis and is a clinically useful antineoplastic agent.

 

10-5110

07/20

FITC-Tyramide | Signal amplification reagent for immunoassays

Reagent for use in catalyzed reporter deposition (CARD) signal amplification1 protocols in a variety of immunoassays in which horseradish peroxidase catalyzes local deposition of FITC tyramide.

 

10-5112

07/20

Xanomeline tartrate | Selective M1 muscarinic agonist

Functionally-selective M1 muscarinic receptor agonist. Displays positive cognitive and behavioral effects in schizophrenia and Alzheimer’s disease. Suppresses proinflammatory cytokine responses and improves survival in sepsis.

 

10-3001

06/20

Emetine hydrochloride | Protein synthesis inhibitor

A useful agent for inhibiting protein synthesis in eukaryotic cells by virtue of its inhibition of the ribosome 40S subunit. Inhibits Zika and Ebola virus in vitro and in vivo, also inhibits SARS-CoV-2 replication in cells

 

10-5087

06/20

Boceprevir | Antiviral, SARS-CoV2 Mpro inhibitor

Directly inhibits Hepatitis C virus (HCV) NS3 protease. This blocks NS3 autoactivation, and subsequent cleavage and maturation of other viral proteins necessary for replisome assembly.

 

 

10-5085

05/20

Remodelin | Acetyltransferase NAT10 inhibitor

Potent and selective inhibitor of N-acetyltransferase 10 (NAT10) which us capable of acetylating microtubules and histones. Improves nuclear architecture, chromatin organization and fitness, normalizing progeric and aging cells.

 

10-3816

05/20

Guggulsterone-(Z) | FXR antagonist

Natural steroid which lowers cholesterol and acts as an FXR antagonist. Induces differentiation of pluripotent stem cells to dopaminergic neurons.

 

10-2822

05/20

Omeprazole | Proton pump inhibitor/ Antiviral

H+,K+-ATPase inhibitor, clinically useful antisecretory and antiulcer agent. Displays broad spectrum antiviral activity and enhances the efficacy of remdesivir.

 

10-5044

05/20

GKT-37831 | NADPH oxidase NOX1/4 inhibitor

GKT137831 inhibits NADPH oxidase BOX1/4 and blocks erastin-stimulated ROS production.

 

 

10-4090

04/20

TIC10 | Mitochondrial caseinolytic protease P activator / Anticancer agent

Novel anti-cancer compound that acts via early-stage integrated stress response activation leading to selective cancer cell death

 

10-4468

04/20

Roxadustat | Proyl hydroxylase domain inhibitor / HIF stabilizer

Pan-prolyl hydroxylase domain (PHD) inhibitor that stabilizes hypoxia-inducible factor (HIF) leading to erythropoiesis.

 

10-4384

04/20

Tiagabine hydrochloride | GABA transporter 1 (GAT1) inhibitor

Clinically useful anticonvulsant that inhibits both neuronal and glial GABA re-uptake

 

10-4471

04/20

Favipiravir | Inhibitor of viral RNA-dependent RNA polymerase

Inhibitor of viral RNA-dependent RNA polymerase with activity against influenza viruses A,B and C as wells as a wide range of other viruses.

 

10-4483

04/20

Oseltamivir Phosphate | Neuraminidase inhibitor / Antiviral

Potent viral neuraminidase inhibitor and clinically useful treatment for influenzas A and B.

 

10-4484

04/20

Ritonavir | HIV1/2 protease inhibitor

Clinically useful HIV-1/HIV-2 protease inhibitor. Potent inhibitor of cytochrome P450 3A4.

 

10-4960

04/20

GRL-0496 | SARS-CoV 3CLpro inhibitor

Potent inhibitor of severe acute respiratory syndrome-coronavirus chymotrypsin-like protease.

 

10-4965

04/20

GRL-0617 | Potent SARS-CoV PLpro inhibitor

Potent noncovalent inhibitor of severe acute respiratory syndrome-coronavirus papain-like protease. Inactive against human DUB-like proteases.

 

10-3050

04/20

Nelfinavir mesylate | HIV protease inhibitor / Anticancer activity

Clinically useful anti-HIV acting via inhibition of HIV-1 proteases. Also displays efficacy in cancer, malaria, tuberculosis and SARS.

 

10-3474

04/20

Prochlorperazine maleate | Endocytosis inhibtior

Inhibits dynamin and clathrin-mediated endocytosis. Increases tumor cell antigen presentation.

 

10-4032

04/20

Tazemetostat | EZH2 inhibitor

Potent and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2

 

10-5064

04/20

Ponatinib | Bcr-Abl multikinase inhibitor

Highly potent pan-Bcr-Abl and multikinase inhibitor, suppressing the activity of native Bcr-Abl as well as the mutants T315I, Q252H, Y253F, M351T and H396P. Protects against influenza A virus-induced death by suppressing cytokine storm in mouse models.

 

10-3613

03/20

Santacruzamate A | Ultrapotent HDAC2 inhibitor

Highly potent and selective inhibitor of HDAC2 isolated from the Panamanian marine cyanobacterium cf. Symploca.

 

10-3965

03/20

Brequinar sodium | Dihydroorotate dehydrogenase inhibitor, antiviral

Inhibitor of dihydroorotate dehydrogenase with broad antiviral activity against flaviviruses, positive-strand RNA alphaviruses, negative-strand RNA rhabdoviruses, influenza A and B viruses and HIV.

 

10-5046

03/20

Roxatidine | Histamine H2 antagonist, antiulcer, anti-inflammatory

Novel histamine H2 receptor antagonist that suppresses inflammatory response via inhibition of NF&kappa>B and p38 MAPK activation in macrophages.

 

10-3970

03/20

N4-Hydroxycytidine | Novel antiviral

N4-Hydroxycytidine is the active molecule in the antiviral pro-drug clinical candidate EIDD-2801 with action against a broad range of viruses including coronaviruses

 

10-2196

03/20

Camostat mesylate | Serine protease inhibitor, antiviral, anti-inflammatory activity

Reduces infection of Calu-3 lung cells by SARS-CoV-2 (responsible for COVID-19) via inhibition of the serine protease TMPRSS2 required for viral spike protein priming.

 

10-2712

03/20

Scriptaid | HDAC inhibitor

Inhibits HDACs 1,3 and 8. Induces cell cycle arrest and epigenetic changes in colon cancer cells.

 

10-2790

03/20

Dihydroresveratrol | Resveratrol metabolite

Glucuronide conjugates of dihydroresveratrol are found in human urine after oral intake of resveratrol dietary supplements.

 

10-1561

03/20

DY131 | Estrogen-related receptor ERRβ and ERRγ agonist

Selective agonist at estrogen-related receptors ERRβ and ERRγ with minimal activity at ERRα, ERα and ERβ. Displays antiproliferative activity in prostate cancer cells.

 

10-3960

03/20

PK150 | Sorafenib analog with unique antibacterial properties

Displays significant antibacterial activity against S. aureus NSTC8325, vancomycin-resistant enterococci and M. tuberculosus. Inactive against Gram-negative bacteria

 

10-2955

03/20

Leelamine | Intracellular cholesterol inhibitor

Induces cholesterol accumulation in lysosomal/endosomal cell compartments via inhibition of autophagic flux

 

10-4810

02/20

NU7441 | DNA-PK inhibitor

Potent and selective ATP-competitive inhibitor of DNA-dependent protein kinase. Increases radio/chemosensitivity of various cancer cell lines.

10-4810

02/20

Crenolanib | PDGF and FLT3 inhibitor

Potent inhibitor of PDGFR and FLT3 that binds only to the active kinase configuration.

10-4778

02/20

AZ3146 | Mps 1kinase inhibitor

Potent and selective inhibitor of monopolar spindle 1 that decreases hepatocellular carcinoma growth in vitro.

10-4771

02/20

AZD7762 | Checkpoint Kinase 1/2 inhibitor

Potent and selective inhibitor of checkpoint kinases 1 and 2. It abrogates DNA damage-induced S and G2 checkpoints and enhances the efficacy of DNA damaging agents such as gemcitabine and irinotecan.

10-4779

02/20

SNS-314 mesylate | Aurora kinase inhibitor

Potent and selective Aurora kinase inhibitor. Able to inhibit proliferation in a wide panel of human cancer cell lines.

10-3901

02/20

Elafibranor | PPARalpha/delta agonist

Able to decrease plasma triglycerides levels, increase HDL cholesterol levels in human studies, and improve hepatic and peripheral insulin sensitivity.

10-2040

02/20

Levetiracetam | Anticonvulsant

Clinically useful non classical anticonvulsant believed to act through binding to SV2A. No effect on voltage-dependent Na+ channels, GABAergic transmission, or affinity for either GABAergic or glutaminer rgic eceptor.

10-3900

02/20

Tigecycline | Antibiotic

Clinically useful antibiotic that has also been shown to be selectively toxic to human acute myeloid leukemia cells over normal hematopoietic cells.

10-4818

02/20

Volasertib | Potent and selective inhibitor of Polo-like kinase 1

Potent and selective inhibitor of Polo-like kinase 1 that has shown efficacy in multiple solid xenograft tumor models and in clinical studies of patients with acute myeloid leukemia.

10-4784

02/20

Fruquintinib | Potent and selective inhibitor of VEGFR kinase

Potently and selectively inhibits VEGF/VEGFR signaling and cell proliferation in HUVECs and HLECs and prevents angiogenesis in vitro.

10-4675

02/20

AZ20 | ATR kinase inhibitor

Combination therapy with AZ20 and gemcitabine resulted in synergistic inhibition of tumor cell growth and cell death initiation in pancreatic cancer cell lines.

10-4804

02/20

AZD1152-HQPA | Aurora B kinase inhibitor

Highly selective inhibitor of Aurora kinase B that inhibits the growth of tumors in multiple cancer models.

10-4017

02/20

Lomeguatrib | MGMT inhibitor

Potent inhibitor of O6-Methylguanine-DNA Methyltransferase (MGMT), an important DNA repair protein.

10-4531

02/20

Methoprene Acid | Selective RXR agonist

Binds directly and selectively to the retinoid X receptor (RXR) acting as a transcriptional activator with no activity at RAR. Negatively regulates thrombosis and hemostasis.

10-3648

02/20

ML-335 | Trek-1,2 activator

Novel, selective TREK-1,2 activator with EC50s of 14.3 and 5.2 µM

10-3756

02/20

NOTUMib-1 | NOTUM inhibitor, restores Wnt signaling

Inhibits the carboxylesterase activity of NOTUM, IC50=0.085 µM, and restores Wnt signaling.

10-1525

02/20

MitoBloCK-12 | Mitochondrial import inhibitor

Blocks translocation of a mutant form of alanine: glyoxylate aminotransferase (AGT) to the mitochondria and restores AGT trafficking to peroxisomes.

10-3631

02/20

N-Eicosanoyl serotonin | Neuroprotective

Inhibits the PP2A methylesterase maintaining PP2A in a highly active state leading to hyperphosphorylat αed -synuclein.

10-3712

02/20

DO264 | ABHD12 inhibitor

Potent, reversible competitive inhibitor of ABHD12 (α/β-hydrolase domain-containing 12) which shows negligible interaction with other serine hydrolases.

10-3321

02/20

Rucaparib phosphate | PARP1 inhibitor

Potent PARP1 inhibitor. Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.

10-2768

02/20

Pomalidomide | Cereblon ubiquitination inhibitor

Inhibits the E3 ubiquitin ligase cereblon (CRBN). Displays antiangiogenic and immunomodulatory activity in vivo potently inhibiting the production of TNF alpha and IL-2.

10-4230

02/20

Imiquimod | TLR7 agonist

Toll-like receptor 7/8 agonist with anti-viral and anti-tumor properties. Enhances innate immune system leading to Th1-mediated antitumor immune response.

10-2671

02/20

Norfluoxetine HCl | Fluoxetine Metabolite

Induces long QT syndrome via slow delayed rectifier potassium current block. Time dependent inhibitor of CYP2C19 and CYP3A4.

10-4806

02/20

Acalabrutinib | Highly selective BTK inhibitor

Hghly selective, potent (IC50 = 3nM), and irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Significantly inhibits BCR signaling, inhibits tumor proliferation, and reduces tumor burden.

10-4757

02/20

Ibrutinib | BTK inhibitor

Very potent (IC50 = 0.5nM) irreversible inhibitor of Bruton tyrosine kinase (BTK) that blocks activation of the B-cell antigen receptor (BCR).